

**MPHARM SEM I (CBCS REVISED)**

**QUESTION BANK FOR PRODUCT DEVELOPMENT AND TECHNOLOGY  
TRANSFER**

**1. Example of a thermoplastic packaging material is**

- a) **Polystyrene**
- b) Phenol formaldehyde
- c) Urea formaldehyde
- d) Melamine formaldehyde

**2. Sorption is**

- a) the transmission of gases, vapors or liquids through plastic packaging material
- b) removal of constituents from the packaging material by the drug product
- c) **removal of constituents from the drug product by the packaging material**
- d) chemical interaction with contents

**3. Most expensive rubber as packaging material is**

- a) Butyl rubber
- b) Nitrile rubber
- c) Chloroprene rubber

**d) Silicon rubbers**

**4. Fragmentation Tests are performed on following packaging material**

- a) **Rubber closures**
- b) Metal tubes
- c) Plastic bottles
- d) Ampoules

**5. Which amongst following is an example of primary packaging**

- a) Wrapper to contain primary pack
- b) Box to contain primary pack

c) Labels, patient information leaflet

**d) Ampoule, vial, infusion fluid container, dropper bottle**

**6. Glass is manufactured by all except one method**

a) Blowing

**b) pulling**

c) casting

d) drawing

**7. Degree of concern associated with route of administration is highest for**

**a) Injections**

b) Topical solutions

c) Nasal aerosols

d) Topical sprays

**8. Aseptic systems commercially sterilize the product**

a) with the package

b) only

c) after packing

**d) separately from the package**

**9. HTST stands for**

**a) high temperature short time**

b) High throughput screen and testing

c) High temperature screen time

d) High temperature short test

**10. Regulatory requirements for which GHTF class of medical devices are highest**

a) A

**b) D**

c) B

d) C

**11. Which of the following is NOT needed for an investigational new drug application?**

- a) Animal pharmacology and toxicology
- b) Manufacturing information
- c) Clinical protocols and Investigator Information

**d) Phase III trial data**

**12. Which technique is the less common method used to protect the integrity of clinical trial results?**

**a) Single blinding**

- b) Double blinding
- c) Randomization
- d) Placebo and control groups

**13. What is a synonym/description for the Phase 4 trials?**

**a) Post Marketing Surveillance**

- b) Pre-Marketing Surveillance
- c) Pre-FDA Approval
- d) Post FDA Approval

**14. On which two criteria does the FDA classify NDAs?**

- a) Novelty of the active ingredient and time to market
- b) Balance between safety and effectiveness
- c) Novelty of the active ingredient and clinical improvement**
- d) Clinical improvement and effectiveness of product

**15. What is the primary focus of Phase 3 Clinical testing?**

- a) How to manage costs.

**b) The collection and analysis of highly specific efficacy end-point data.**

c) The optimal range of effective dosage.

d) The analysis of data results from the small-subset target population.

**16. Which is the primary goal/major milestone of preclinical development?**

**A. Filing an IND application with the FDA**

B. Identifying the target population for the lead compound that is being developed

C. Aligning the development process with the strategic aims of the company

D. To determine anticipated revenue

**17. What are the two greatest challenges for the Development team?**

A. Managing risks and complying with FDA requirements

B. Improving time to market and decreasing toxicity

**C. Accelerating time to market and managing risk**

D. Complying with FDA requirements and improving efficacy

**18. This is a minor detail, but to hit home the concept of how few drugs make it to market, please fill in the blanks (straight out of the book): For every \_\_\_\_\_ compounds that enter preclinical testing, only \_\_\_\_\_ go to clinical development, and only \_\_\_\_\_ win FDA approval.**

a) 1,000, 100, 1

**b) 250, 5, 1,**

c) 1, 5, 250

d) 1, 100, 1,000

**19. What is the approximate ratio of potential compounds the beginning of Development to number of products that ultimately get FDA approval?**

- a) 1:10
- b) 1:100
- c) 1:1,000**
- d) 1:10,000

**20. On what does Phase 1 clinical testing test?**

- a) Animal subjects
- b) Healthy human volunteers
- c) Widespread differentiated population
- d) Large-scale tests in people with the target disease/population**

**21. Which one of the following is NOT a physical property of drug substance being evaluated during preformulation studies?**

- a) Degradation profile**
- b) Solubility
- c) Polymorphism
- d) Crystalline or amorphous nature

**22. What are NOT organoleptic properties of drugs?**

- a) Appearance
- b) Colour
- c) Odour
- d) moisture content**

**23. Excipients are added to tablet dosage form to improve processability. An ideal excipient should have all these properties EXCEPT**

- a) Non-toxic
- b) Physiologically active**
- c) Stable
- d) Low cost

**24. Which is the correct ICH guidelines for Stability studies?**

- a) ICH Q1**
- b) ICH Q3
- c) ICH Q8
- d) ICH Q10

**25. Which is the correct stability study condition for refrigerated product?**

- a)  $40\pm 2^{\circ}\text{C}$  and  $75\pm 5\%$  RH
- b)  $25\pm 2^{\circ}\text{C}$  and  $60\pm 5\%$  RH**
- c)  $30\pm 2^{\circ}\text{C}$  and  $85\pm 5\%$  RH
- d)  $50\pm 2^{\circ}\text{C}$  and  $75\pm 5\%$  RH

**26. Which is the correct stability zone for India?**

- a) Zone I
- b) Zone II
- c) Zone IVa
- d) Zone IVb**

**27: Which one of the following is NOT true? Different polymorphs forms of a drug can have different:**

- a) Melting points

**b) Molecular formulae**

c) Solubilities

d) Crystal habits

**28: Which one of the following is NOT true?**

a) Drugs can be hydrophilic or hydrophobic

**b) Hydrophobic drugs are easily wetted**

c) Hydrophobic drugs have low solubility in water

d) Hydrophobic drugs dissolve slowly

**29: Which one of the following is NOT true of crystalline solids?**

a) They have long range order

b) They have short range order

**c) They contain a random arrangement of constituents**

d) They have sharp, well-defined melting points

**30. Sieving method for determination of particle size uses a series of standard sieves calibrated by the.....**

**a) National Bureau of standards**

b) IUPAC

c) ICH

d) EMEA

**31. Which water is used for hand washing in change room of pharmaceutical manufacturing plant?**

a) Potable water

- b) Sterile water
- c) Purified water
- d) Soap water**

**32. Which of the following drying method is used in pharma industry for drying of soft gelatin capsule?**

- a) Vacuum drying
- b) Truck drying
- c) Fluid bed drying
- d) Tumble drying**

**33. If all the processing equipment and machines are arranged according to the sequence of operations of a product the layout is known as**

- a) Product layout**
- b) Process layout
- c) Fixed position layout
- d) Combination layout

**34. Which of the following investigations are performed during preformulation investigations of pharmaceuticals?**

- a) Solubility investigations**
- b) Melting point investigations
- c) Stability investigations
- d) Relative harmlessness investigations

**35. Which of the following facility layout is best suited for the intermittent type of production, which is a method of manufacturing several different products using the same production line?**

a) Product layout

**b) Process layout**

c) Fixed position layout

d) Cellular manufacturing layout

**36. Which of the following is not a semisolid dosage form**

a) Paste

b) Creams

c) Ointments

**d) Suspensions**

**37. Class 10,000 is:**

a) Particle count not to exceed a total of 10,000 particles per cubic foot of a size  $5\mu$  and larger

b) Particle count not to exceed a total of 10,000 particles per cubic foot of a size  $0.5\mu$  and smaller

c) Particle count not to exceed a total of 100,000 particles per cubic foot of a size  $0.5\mu$  and larger

**d) Particle count not to exceed a total of 10,000 particles per cubic foot of a size  $0.5\mu$  and larger**

**38. The efficiency of HEPA filter is:**

**A) remove at least 99.97% of airborne particles 0.3 micrometers ( $\mu\text{m}$ ) in diameter.**

B) remove at least 100% of airborne particles 0.3 micrometers ( $\mu\text{m}$ ) in diameter.

C) remove at least 99.97% of airborne particles 2 micrometers ( $\mu\text{m}$ ) in diameter.

D) remove at least 97.99% of airborne particles 0.3 micrometers ( $\mu\text{m}$ ) in diameter.

**39. Which of the following is NOT the principle problem areas exists in plastic containers:**

a) Leaching

**b) Hardness**

c) Permeation

d) Sorption

**40. Powdered glass test challenges the leaching potential of:**

**a) Exterior structure of glass**

b) Plastic containers

c) Interior structure of glass

d) Intact surface of glass

**41. Process innovation refers to:**

a) the development of a new service.

b) the development of a new product.

**c) the implementation of a new or improved production method.**

d) the development of new products or services.

**42. Following establishment of a dominant design in the product life cycle, what would you expect to happen?**

a) Emphasis on product innovation rather than process innovation.

**b) Emphasis on process innovation rather than product innovation.**

c) Competition to increase as new firms enter the industry.

d) Competition to decrease as more firms exit than enter the industry.

**43. Which of the following is not a mode of international technology transfer?**

a) joint ventures

b) licensing

**c) patents**

d) industrial espionage

**44. Technological progress is a three-step process of**

a) creation, pricing, and marketing

**b) invention, innovation, and diffusion**

c) manufacturing, venturing, and promotion

d) start-ups, imitation, and creative destruction

**45. Guidelines for Technology Transfer and Pharmaceutical Quality Systems is**

a) ICH Q1

b) ICH Q3

c) ICH Q8

**d) ICH Q10**

**46. What potential advantages can be gained from involving overseas subsidiaries in R&D activities?**

a) Local subsidiaries offer financial advantages such as lower land and labour costs.

b) Local subsidiaries offer access to local companies.

c) Local subsidiaries offer access to technical knowledge and skills.

**d) Local subsidiaries offer financial advantages as well as access to local markets, technical knowledge and skills.**

**47. The fundamental challenge of knowledge transfer in multinational firms is:**

a) transferring explicit knowledge across borders.

**b) transferring tacit knowledge across borders.**

c) creating tacit knowledge in overseas subsidiaries.

d) transferring tacit and explicit knowledge across borders.

**48. Innovation can help to provide a temporary competitive advantage when:**

a) barriers to entry are high.

**b) barriers to imitation are low and intellectual property rights are difficult to enforce.**

c) there are few other competitors.

d) barriers to entry are low.

**49. Outsourcing of innovation globally is more likely where:**

**a) Innovations are autonomous**

b) Innovations are systemic

c) Innovations are systemic or autonomous

d) Innovations are made by service sector firms

**50. Established firms relative to new firms are better at:**

a) all types of innovation.

**b) innovation which is competence-enhancing.**

c) innovation which is competence-destroying.

d) Innovation which is disruptive.